0
Back To Top Jump Location
Sign In  | Cart
Left Shadow
Right Shadow
Correspondence |

Reply

Patrizio Lancellotti, MD, PhD; Julien Magne, PhD
[+] Author Information

University Hospital Sart Tilman, Department of Cardiology, B-4000 Liege, Belgium

American College of Cardiology Foundation

J Am Coll Cardiol. 2012;59(23):2123-2123. doi:10.1016/j.jacc.2012.02.039
Published online

We would like to thank Drs. Guntheroth and Parras for their interest in our study, which underlined that the assessment of aortic stenosis (AS) severity should integrate the flow-gradient pattern to the classic measurement of aortic valve area (1). The reason is that most of the echocardiographic parameters used to assess the severity of AS are flow dependent. As a general rule, a low transvalvular gradient (<40 mm Hg) or velocity (<4 m/s) does not exclude the presence of a severe AS in patients with small aortic valve areas and preserved left ventricular (LV) ejection fraction. In addition, a preserved LV ejection fraction (>50%) does not exclude the presence of myocardial systolic dysfunction and low transvalvular flow in AS. Such rules are also applicable to congenital AS, particularly when concomitant aortic regurgitation exists (2).

In daily practice, the discrepancy between gradient and aortic valve area may potentially lead to an underestimation of AS and symptom severity and therefore to an inappropriate delay of aortic valve replacement (AVR). Unless related to concomitant valvular (mitral or aortic) regurgitation, potential causes for these discordances include: 1) measurement errors; 2) small body size; 3) paradoxical low-flow AS; and 4) inconsistent grading related to intrinsic discrepancies in guideline criteria. As a first step, the best rule of the thumb is to confirm the low-flow state using volumetric approaches (2- or 3-dimensional echocardiography). If the stroke volume measured by these independent methods is consistent with the stroke volume measured using the LV outflow tract, one can be reassured of the accuracy of the measurement of stroke volume. Such a low-flow state represents a witness of intrinsic myocardial dysfunction and a more advanced disease process. It could be associated with either high-gradient or low-gradient AS.

In our study, all patients were regularly followed in our outpatient heart valve clinic. Both soft and hard events were considered in a composite end point defined as cardiovascular death or need for AVR motivated by the development of symptoms or LV dysfunction. This eliminates bias related to the inclusion of AVR not dictated by symptoms. As mentioned by Dr. Parras, there are some discrepancies in the hazard ratios reported in the “Results” section of the report and in Table 4 [(1)]. Nevertheless, these differences did not affect the interpretation of the results. In fact, such differences are explained by different multivariate models used in the 2 sections. According to the statistical review, it was suggested, to avoid overfitting of the models, not to include variables with high degrees of colinearity. These changes were reported in Table 4 [(1)], but not in the text, in which the multivariate model including all variables was provided. Peak aortic velocity and mean aortic gradient are closely and directly correlated. Therefore, it may be difficult to admit that those variables predict events in a contradictory fashion. However, this reflects the statistical models used. The normal-flow low-gradient entity represented the referent group. This is the reason why the peak aortic velocity or the low-flow pattern predicted the outcome compared with the referent group. However, outcome prediction was more significant in the low-flow low-gradient entity. These results were obtained even if the incidence of the low-flow low-gradient AS pattern was low. Of note, 82% of patients in this category experienced cardiac events during follow-up. Furthermore, chance has no role to play in these results.

The outcomes of patients with low-flow high-gradient AS are nearly identical to those of patients with normal-flow high-gradient AS. When symptomatic, AVR is the only therapy that can significantly improve functional capacity, symptoms, and survival. Paradoxical low-flow low-gradient AS conveys the poorest outcome, even in asymptomatic patients. In this entity, though the benefit of surgery is not proven, AVR may probably be beneficial in selected patients. Of note, even if the data reported by Kang et al. (3) are not applicable to this category, they suggest that early AVR may improve survival. However, before considering surgery, symptoms should be matched to the severity of AS.

References

Lancellotti  P., Magne  J., Donal  E.; Clinical outcome in asymptomatic severe aortic stenosis: insights from the new proposed aortic stenosis grading classification. J Am Coll Cardiol. 59 2012:235-243.
CrossRef | PubMed
Morgan  B.C., Guntheroth  W.G., Baum  D., Merendino  K.A.; Reassessment of operative indication for moderate congenital aortic stenosis. J Thorac Cardiovasc Surg. 49 1965:150-158.
PubMed
Kang  D.H., Park  S.J., Rim  J.H.; Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation. 121 2010:1502-1509.
CrossRef | PubMed

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

References

Lancellotti  P., Magne  J., Donal  E.; Clinical outcome in asymptomatic severe aortic stenosis: insights from the new proposed aortic stenosis grading classification. J Am Coll Cardiol. 59 2012:235-243.
CrossRef | PubMed
Morgan  B.C., Guntheroth  W.G., Baum  D., Merendino  K.A.; Reassessment of operative indication for moderate congenital aortic stenosis. J Thorac Cardiovasc Surg. 49 1965:150-158.
PubMed
Kang  D.H., Park  S.J., Rim  J.H.; Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation. 121 2010:1502-1509.
CrossRef | PubMed

Correspondence

Latest JACC CME

Continuing Medical Education through JACC is a convenient way to fulfill your CME requirements while learning important information about the latest advances in cardiovascular medicine.

April 2013- JACC CME Activity
Repeat Revascularization and Outcome

March 2013- JACC CME Activity
Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction

Feb 2013- JACC CME Activity
Results from the BARI 2D Trial

Jan 2013- JACC CME Activity
Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope

Dec 2012- JACC CME Activity
Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

Nov 2012- JACC CME Activity
A Collaborative Analysis of Individual Patient Data From 10 Randomized Trials

Oct 2012- JACC CME Activity
Radiofrequency Ablation of Premature Ventricular Ectopy Improves the Efficacy of Cardiac Resynchronization Therapy in Nonresponders

Sept 2012- JACC CME Activity
Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease

Aug 2012- JACC CME Activity
Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)

July 2012- JACC CME Activity
Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction

For previous CME quizzes, please follow this link to CardioSource Lifelong Learning and MOC.

 

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.